Developer docs
API playgroundTry for free, no card

Search company profiles

Peprotech, Inc

Full company profile

uuid000dfjr

Namestring
Peprotech, Inc
Legal namestring
PeproTech, Inc.
Websiteurl
peprotech.com
Company typeenum
Private
Founded yearint
1988
Descriptiontext

PeproTech, Inc. is a biotechnology company founded in 1988 and headquartered in Rocky Hill, United States, specializing in the development and production of recombinant cytokines, growth factors, chemokines, neurotrophins, proteases, enzymes, ligands, and receptors based on human, mouse, and rat sequences. The company produces these proteins using bacterial (E. coli), mammalian (HEK293, CHO), and insect cell expression systems, with rigorous in-house quality control spanning N-terminal sequencing, SDS-PAGE, RP-HPLC, mass spectrometry, endotoxin testing, and biological activity assays. PeproTech serves life science researchers, biotech companies, and pharma/biotherapeutics developers, with applications spanning cell culture, signaling pathway research, organoid and 3D disease models, tumor models, and cell and gene therapy production.

Since its acquisition by Thermo Fisher Scientific in 2021, PeproTech has operated as a wholly-owned subsidiary brand under the Gibco portfolio. Its product portfolio spans Research Use Only (RUO) recombinant proteins, animal-origin-free cytokines produced in dedicated facilities with endotoxin levels below 0.1 EU/µg, and PeproGMP-grade cytokines manufactured to meet standards for advanced therapy medicinal product (ATMP) clinical manufacturing. Revenue is generated through one-time product sales of recombinant proteins, distributed globally via Thermo Fisher's e-commerce platform (thermofisher.com), field sales force, and eProcurement systems targeting enterprise biotech and pharma buyers. Pricing is catalog-based for RUO products and quote-based for GMP products, with no public disclosure of standalone financials given its subsidiary status.

Short descriptiontext

PeproTech, founded in 1988 and acquired by Thermo Fisher Scientific in 2021, develops and produces recombinant cytokines, growth factors, and related proteins for life science researchers, biotech firms, and biotherapeutics developers, including GMP-grade materials for cell and gene therapy manufacturing under the Gibco brand.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRocky Hill, United States
HQ citystring
Rocky Hill
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
recombinant proteins, cytokine products, cell culture reagents, growth factors, life science research
Industry2 codes
1Therapeutic Peptides & Protein/Peptide Biologics
CodeHLAAAAAHPrimaryYes
2Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins)
CodeAFAJAHALPrimaryNo
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Recombinant Proteins / Life Science Reagents
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Recombinant Protein Product Sales
TypeOne Time License
Description

PeproTech generates revenue through the sale of recombinant cytokines, growth factors, chemokines, and other proteins under both Research Use Only (RUO) and GMP-grade formulations for life science research through clinical development. The company serves the cell and gene therapy market by providing well-characterized ancillary materials.

openpr.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Supply Chain, Operations, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PeproGMP
Description

GMP-grade recombinant cytokines and growth factors for clinical and advanced therapy medicinal product (ATMP) manufacturing. Based on human sequences and produced in E. coli, designed for clinical trials and cell therapy production.

thermofisher.com
Core offering1 text field

PeproTech develops and manufactures recombinant cytokine and protein products — including cytokines, growth factors, chemokines, neurotrophins, proteases, enzymes, ligands, and receptors — for life-science research. The company offers both Research Use Only (RUO) and GMP-grade (PeproGMP) product lines, with animal-origin-free options available for human, mouse, and rat sequences.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

PeproTech, acquired by Thermo Fisher Scientific in 2021, offers a comprehensive portfolio of recombinant proteins under the Gibco brand, encompassing both research-use-only (RUO) and GMP-grade products. The portfolio includes PeproTech recombinant proteins (cytokines, growth factors, chemokines, neurotrophins, proteases, enzymes, ligands, and receptors), Gibco PeproGMP cytokines for clinical cell and gene therapy manufacturing, RUO recombinant cytokines with rigorous quality control testing, and animal-free cytokines produced in dedicated animal-free facilities. These products serve applications across stem cell research, 3D cell culture/organoid models, cancer cell biology, neurobiology, immunology, and cardiovascular research, supporting the RUO-to-GMP transition for biotherapeutics developers.

Product and service1 record
1Recombinant Cytokines, Growth Factors, Chemokines, Neurotrophins, Proteases, Enzymes, Ligands, and Receptors
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Abcam (now part of Danaher) supplies a broad portfolio of life science research tools including recombinant proteins and antibodies. While not focused solely on cytokines, it competes with PeproTech across the research reagent purchasing workflow of biotech customers.

TypeDirect peer
Description

CellGenix specializes in GMP-grade cytokines and growth factors for cell and gene therapy manufacturing, directly competing with PeproGMP. It is a focused specialist in the clinical ancillary materials space with deep regulatory documentation.

TypeEmerging player
Description

GenScript offers recombinant protein production services and catalog reagents, including cytokines and growth factors. It competes with PeproTech in both research reagents and custom protein production services.

TypeDirect peer
Description

StemCell Technologies supplies cytokines, growth factors, and cell culture media for stem cell research and cell therapy development. It competes with PeproTech across RUO and GMP reagent categories, particularly in the stem cell and regenerative medicine research market.

TypeDirect peer
Description

Miltenyi Biotec manufactures recombinant cytokines and growth factors for cell therapy and immunology research, including GMP-grade products. It overlaps significantly with PeproTech's PeproGMP line and competes for cell and gene therapy ancillary material business.

TypeEmerging player
Description

Sino Biological is a Chinese manufacturer of recombinant proteins, antibodies, and cytokines with a rapidly expanding catalog. It competes with PeproTech on price across research-grade reagents and is gaining share in international markets.

TypeEmerging player
Description

Proteintech manufactures antibodies and recombinant proteins for life science research with a growing catalog of cytokines and growth factors. It competes with PeproTech primarily in the academic and biotech RUO reagent market.

TypeDirect peer
Description

Bio-Techne's R&D Systems brand is the market-leading recombinant cytokine and growth factor supplier for life science research. It directly competes with PeproTech across RUO and GMP product lines and is the closest comparable in terms of catalog breadth, brand recognition, and scientific publication footprint.

TypeDirect peer
Description

Akron Biotech manufactures GMP-grade cytokines, growth factors, and ancillary materials for cell and gene therapy developers. It is a direct competitor in the PeproGMP addressable market for ATMP manufacturing inputs.

TypeBroad incumbent
Description

Revvity's BioLegend brand supplies recombinant cytokines, antibodies, and flow cytometry reagents for life science research. It competes with PeproTech in the immunology and cell biology reagent market and serves overlapping biotech and academic customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Peprotech, Inc

Recombinant Proteins / Life Science Reagentspeprotech.com

PeproTech, founded in 1988 and acquired by Thermo Fisher Scientific in 2021, develops and produces recombinant cytokines, growth factors, and related proteins for life science researchers, biotech firms, and biotherapeutics developers, including GMP-grade materials for cell and gene therapy manufacturing under the Gibco brand.

What Peprotech, Inc does

PeproTech, Inc. is a biotechnology company founded in 1988 and headquartered in Rocky Hill, United States, specializing in the development and production of recombinant cytokines, growth factors, chemokines, neurotrophins, proteases, enzymes, ligands, and receptors based on human, mouse, and rat sequences. The company produces these proteins using bacterial (E. coli), mammalian (HEK293, CHO), and insect cell expression systems, with rigorous in-house quality control spanning N-terminal sequencing, SDS-PAGE, RP-HPLC, mass spectrometry, endotoxin testing, and biological activity assays. PeproTech serves life science researchers, biotech companies, and pharma/biotherapeutics developers, with applications spanning cell culture, signaling pathway research, organoid and 3D disease models, tumor models, and cell and gene therapy production.

Since its acquisition by Thermo Fisher Scientific in 2021, PeproTech has operated as a wholly-owned subsidiary brand under the Gibco portfolio. Its product portfolio spans Research Use Only (RUO) recombinant proteins, animal-origin-free cytokines produced in dedicated facilities with endotoxin levels below 0.1 EU/µg, and PeproGMP-grade cytokines manufactured to meet standards for advanced therapy medicinal product (ATMP) clinical manufacturing. Revenue is generated through one-time product sales of recombinant proteins, distributed globally via Thermo Fisher's e-commerce platform (thermofisher.com), field sales force, and eProcurement systems targeting enterprise biotech and pharma buyers. Pricing is catalog-based for RUO products and quote-based for GMP products, with no public disclosure of standalone financials given its subsidiary status.

Peprotech, Inc firmographics

Firmographics
Name
Peprotech, Inc
Legal name
PeproTech, Inc.
Website
https://peprotech.com
Company type
Private
Founded year
1988
Operating status
Acquired
Headcount range
51–100 employees
Short description
PeproTech, founded in 1988 and acquired by Thermo Fisher Scientific in 2021, develops and produces recombinant cytokines, growth factors, and related proteins for life science researchers, biotech firms, and biotherapeutics developers, including GMP-grade materials for cell and gene therapy manufacturing under the Gibco brand.
Ownership category
akta.pro rank

Peprotech, Inc industry classification

Industry
Product category
Recombinant Proteins / Life Science Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro primary industry
Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
akta.pro secondary industry
Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins) (AFAJAHAL)

Keywords

  • Recombinant proteins
  • Cytokine products
  • Cell culture reagents
  • Growth factors
  • Life science research

Where Peprotech, Inc is headquartered

Location

Headquarters

HQ city
Rocky Hill
HQ country
United States
HQ region
North America

Markets served

Peprotech, Inc business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel

Revenue model

  1. Recombinant Protein Product Sales: PeproTech generates revenue through the sale of recombinant cytokines, growth factors, chemokines, and other proteins under both Research Use Only (RUO) and GMP-grade formulations for life science research through clinical development. The company serves the cell and gene therapy market by providing well-characterized ancillary materials.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Peprotech, Inc product offering

Product offering

Core offering

PeproTech develops and manufactures recombinant cytokine and protein products — including cytokines, growth factors, chemokines, neurotrophins, proteases, enzymes, ligands, and receptors — for life-science research. The company offers both Research Use Only (RUO) and GMP-grade (PeproGMP) product lines, with animal-origin-free options available for human, mouse, and rat sequences.

Product overview

PeproTech, acquired by Thermo Fisher Scientific in 2021, offers a comprehensive portfolio of recombinant proteins under the Gibco brand, encompassing both research-use-only (RUO) and GMP-grade products. The portfolio includes PeproTech recombinant proteins (cytokines, growth factors, chemokines, neurotrophins, proteases, enzymes, ligands, and receptors), Gibco PeproGMP cytokines for clinical cell and gene therapy manufacturing, RUO recombinant cytokines with rigorous quality control testing, and animal-free cytokines produced in dedicated animal-free facilities. These products serve applications across stem cell research, 3D cell culture/organoid models, cancer cell biology, neurobiology, immunology, and cardiovascular research, supporting the RUO-to-GMP transition for biotherapeutics developers.

Differentiator

Problem solved

Functional benefit

Brands

  • PeproGMP: GMP-grade recombinant cytokines and growth factors for clinical and advanced therapy medicinal product (ATMP) manufacturing. Based on human sequences and produced in E. coli, designed for clinical trials and cell therapy production.

Products and services

  • Recombinant Cytokines, Growth Factors, Chemokines, Neurotrophins, Proteases, Enzymes, Ligands, and Receptors

Companies that use Peprotech, Inc

Customer profile

Segments2 records

Ideal customer profiles2 records

Peprotech, Inc technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Peprotech, Inc partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Peprotech, Inc competitors and assessment

Company assessment

Broad incumbents

  • Abcam: Abcam (now part of Danaher) supplies a broad portfolio of life science research tools including recombinant proteins and antibodies. While not focused solely on cytokines, it competes with PeproTech across the research reagent purchasing workflow of biotech customers.
  • Revvity (BioLegend): Revvity's BioLegend brand supplies recombinant cytokines, antibodies, and flow cytometry reagents for life science research. It competes with PeproTech in the immunology and cell biology reagent market and serves overlapping biotech and academic customers.

Direct peers

  • CellGenix: CellGenix specializes in GMP-grade cytokines and growth factors for cell and gene therapy manufacturing, directly competing with PeproGMP. It is a focused specialist in the clinical ancillary materials space with deep regulatory documentation.
  • StemCell Technologies: StemCell Technologies supplies cytokines, growth factors, and cell culture media for stem cell research and cell therapy development. It competes with PeproTech across RUO and GMP reagent categories, particularly in the stem cell and regenerative medicine research market.
  • Miltenyi Biotec: Miltenyi Biotec manufactures recombinant cytokines and growth factors for cell therapy and immunology research, including GMP-grade products. It overlaps significantly with PeproTech's PeproGMP line and competes for cell and gene therapy ancillary material business.
  • Bio-Techne (R&D Systems): Bio-Techne's R&D Systems brand is the market-leading recombinant cytokine and growth factor supplier for life science research. It directly competes with PeproTech across RUO and GMP product lines and is the closest comparable in terms of catalog breadth, brand recognition, and scientific publication footprint.
  • Akron Biotech: Akron Biotech manufactures GMP-grade cytokines, growth factors, and ancillary materials for cell and gene therapy developers. It is a direct competitor in the PeproGMP addressable market for ATMP manufacturing inputs.

Emerging players

  • GenScript: GenScript offers recombinant protein production services and catalog reagents, including cytokines and growth factors. It competes with PeproTech in both research reagents and custom protein production services.
  • Sino Biological: Sino Biological is a Chinese manufacturer of recombinant proteins, antibodies, and cytokines with a rapidly expanding catalog. It competes with PeproTech on price across research-grade reagents and is gaining share in international markets.
  • Proteintech: Proteintech manufactures antibodies and recombinant proteins for life science research with a growing catalog of cytokines and growth factors. It competes with PeproTech primarily in the academic and biotech RUO reagent market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Peprotech, Inc social profiles

Digital presence

Peprotech, Inc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Peprotech, Inc leadership team

Management profile

Number of profiles

Profiles2 records

Peprotech, Inc funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Peprotech, Inc M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Peprotech, Inc

What does Peprotech, Inc do?

PeproTech develops and manufactures recombinant cytokine and protein products — including cytokines, growth factors, chemokines, neurotrophins, proteases, enzymes, ligands, and receptors — for life-science research. The company offers both Research Use Only (RUO) and GMP-grade (PeproGMP) product lines, with animal-origin-free options available for human, mouse, and rat sequences.

Is Peprotech, Inc a public or private company?

Peprotech, Inc is a private company. It is classified as corporate owned and is currently acquired.

When was Peprotech, Inc founded?

Peprotech, Inc was founded in 1988. It employs 51 to 100 people.

Where is Peprotech, Inc based?

Peprotech, Inc is headquartered in Rocky Hill, United States, in the North America region.

How does Peprotech, Inc make money?

One revenue line is on record: recombinant Protein Product Sales.

Who are Peprotech, Inc's main competitors?

Broad incumbents on record are Abcam and Revvity (BioLegend). Direct peers are CellGenix, StemCell Technologies, Miltenyi Biotec, Bio-Techne (R&D Systems) and Akron Biotech. Emerging players are GenScript, Sino Biological and Proteintech.

Does Peprotech, Inc have an API?

No public API is recorded for Peprotech, Inc.

What industry is Peprotech, Inc in?

Peprotech, Inc's product category is Recombinant Proteins / Life Science Reagents. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of AFAJAHAL, Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireRecombinant Proteins Market to reach USD 8.08 Billion by 2035 at 8.0% CAGRThe global recombinant proteins market is projected to grow from USD 3.46 billion in 2024 to USD 8.08 billion by 2035, an 8.0% CAGR. Growth is driven by chronic disease demand, production advances, and personalized medicine, with North America leading at 46.19% share.openPR.comRecombinant Proteins Market Size Set to Reach USD 14.6 Billion by 2034 amid Rising Biopharmaceutical Demand and Personalized Medicine ExpansionThe Global Recombinant Proteins Market is valued at USD 4.9 billion in 2025 and is projected to reach USD 14.6 billion by 2034, growing at a CAGR of 13.0%, driven by advances in recombinant DNA technology, increasing demand for biopharmaceuticals, and personalized medicine. North America holds approximately 42.5% market share in 2025, while Asia-Pacific is emerging as the fastest-growing region due to increasing biopharmaceutical investments. Key recent strategic transactions include Danaher Corporation's acquisition of Abcam Plc for USD 5.7 billion, Thermo Fisher Scientific's acquisition of PeproTech, and GenScript's opening of an automated protein manufacturing facility in Singapore.PR NewswireGlobal Recombinant DNA Technology Market Report 2023: Increasing Number of Chronic Diseases Drives GrowthResearchAndMarkets.com published a global recombinant DNA technology market report indicating the market is expected to grow from $754.97 billion in 2022 to $1.07 trillion in 2027, driven by increasing chronic diseases and technological advancements. The report identifies major players including Thermo Fisher Scientific, Amgen, Novartis, and Pfizer, and covers market segmentation by product type, component, application, and end-use. In January 2022, Thermo Fisher Scientific acquired PeproTech for $1.85 billion to complement its cell culture media products with PeproTech's recombinant proteins portfolio.PR NewswireGlobal Recombinant Cell Culture Supplements Market: Focus on Recombinant Supplement Products, Applications, and Region - Analysis and Forecast: 2018 to 2028BIS Research published a market analysis report projecting the global recombinant cell culture supplements market to grow from $230.5 million in 2017 to $788.6 million by 2028, driven by benefits including superior purity, consistency, safety profile, and cost-effectiveness over animal-derived supplements. North America led the market in 2017, with the U.S. contributing approximately 93% of the regional share, while the Asia-Pacific region is expected to witness the highest growth rate during the forecast period. The report identifies key players including Thermo Fisher Scientific, Merck KGaA, and STEMCELL Technologies among the competitive landscape.